<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240457</url>
  </required_header>
  <id_info>
    <org_study_id>330019</org_study_id>
    <nct_id>NCT04240457</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Crosslinking in Eyes With Corneal Ectatic Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Center for Eye Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Center for Eye Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the PXL Platinum 330 device for performing&#xD;
      Corneal Crosslinking in patients with corneal thinning conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for&#xD;
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal&#xD;
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.&#xD;
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,&#xD;
      visual acuity, intraocular pressure and visual function questionnaire assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Treatment of patients with disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomized at outset</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean keratometry in diopters</measure>
    <time_frame>1 year</time_frame>
    <description>Average keratometry across the anterior topography of the cornea computed by a validated topographer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keratoconus</condition>
  <condition>Cornea Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9mW continuous, 10 minutes of illumination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.</intervention_name>
    <description>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria: Criterion 1,2,3 are required for all participants. Participants&#xD;
             must also meet one or more of criteria 4-12 . Criterion 13 is relevant only for&#xD;
             contact lens wearers&#xD;
&#xD;
        Subjects who have one or both eyes that meet criteria 1 and one or more of the following&#xD;
        criteria will be considered candidates for this study:&#xD;
&#xD;
          1. 12 years of age or older&#xD;
&#xD;
          2. Presence of central or inferior steepening.&#xD;
&#xD;
          3. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid&#xD;
             marginal degeneration&#xD;
&#xD;
          4. Presence of one or more findings associated with keratoconus or pellucid marginal&#xD;
             degeneration, such as:&#xD;
&#xD;
               1. Fleischer ring&#xD;
&#xD;
               2. Vogt's striae&#xD;
&#xD;
               3. Decentered corneal apex&#xD;
&#xD;
               4. Munson's sign&#xD;
&#xD;
               5. Rizzutti's sign&#xD;
&#xD;
               6. Apical Corneal scarring consistent with Bowman's breaks&#xD;
&#xD;
               7. Scissoring of the retinoscopic reflex&#xD;
&#xD;
               8. Crab-claw appearance on topography&#xD;
&#xD;
          5. Steepest keratometry (Kmax) value â‰¥ 47.20 D&#xD;
&#xD;
          6. I-S keratometry difference &gt; 1.5 D on the Pentacam map&#xD;
&#xD;
          7. Posterior corneal elevation &gt;16 microns&#xD;
&#xD;
          8. Thinnest corneal point &lt;485 microns&#xD;
&#xD;
          9. Predicted Post LASIK/PRK stromal ablation depth &lt;350 microns or expected keratometry&#xD;
             &gt;47.2 D, or patients undergoing PRK in keratoconus suspect eyes&#xD;
&#xD;
         10. Contact Lens Wearers Only:&#xD;
&#xD;
             a. Removal of contact lenses for the required period of time prior to the screening&#xD;
             refraction:&#xD;
&#xD;
         11. Signed written informed consent&#xD;
&#xD;
         12. Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
         13. Contact Lens Wearers Only:&#xD;
&#xD;
               1. Removal of contact lenses for the required period of time prior to the screening&#xD;
                  refraction:&#xD;
&#xD;
        Contact Lens Type Minimum Discontinuation Time: Soft 1 Week, Soft Extended Wear 2 Weeks,&#xD;
        Soft Toric 3 Weeks, Rigid Gas Permeable 2 Weeks per decade of wear&#xD;
&#xD;
        Exclusion Criteria (any of the following are reasons for exclusion):&#xD;
&#xD;
          1. Eyes classified as either normal or atypical normal on the severity grading scheme.&#xD;
&#xD;
          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the thinnest point in&#xD;
             the eye(s) to be treated.&#xD;
&#xD;
          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster&#xD;
                  keratitis, recurrent erosion syndrome, acanthamoeba, etc.)&#xD;
&#xD;
               2. Clinically significant corneal scarring in the CXL treatment zone that is not&#xD;
                  related to keratoconus, or in the investigator's opinion, will interfere with the&#xD;
                  cross-linking procedure.&#xD;
&#xD;
          4. Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          5. A known sensitivity to study medications&#xD;
&#xD;
          6. Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment or other diagnostic tests.&#xD;
&#xD;
          7. Patients with a current condition that, in the physician's opinion, would interfere&#xD;
             with or prolong epithelial healing&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lubeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arbor Center for Eye Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lubeck, MD</last_name>
    <phone>708-249-1026</phone>
    <email>dr.lubeck@arboreyecare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arbor Center for Eye Care</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lubeck, MD</last_name>
      <phone>708-249-1026</phone>
      <email>dr.lubeck@arboreyecare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

